Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Fluocinonide may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
FOR Metosyn FAPG cream contains fluocinonide which is a corticosteroid (also referred to as a steroid) and reduces inflammation. It is used to treat certain inflammatory, itchy or allergic skin conditions such as eczema, dermatitis, prurigo, psoriasis, lichen planus and discoid lupus erythematosus. It is not normally used to treat large areas of psoriasis because the likelihood of side effects is greater. Corticosteroid creams, ointments and other topical preparations come in four different potencies or strengths. These are known as mild, moderately potent, potent or very potent. Healthcare professionals will usually refer to topical corticosteroid potency rather than strength. A potent or strong corticosteroid has a much stronger effect than a mild corticosteroid when using the same amount. The percentage of active ingredient that is sometimes included on product packaging does not indicate potency. Metosyn FAPG cream is classed as a strong corticosteroid. Your healthcare professional will prescribe or advise a steroid of the appropriate potency for your condition.
E METOSYN FAPG CREAM Do not use Metosyn FAPG cream:
mouth
METOSYN FAPG CREAM Always use Metosyn FAPG cream exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. Unless your doctor tells you differently, put a small amount of cream onto the affected area, three or four times a day. Rub it gently and thoroughly into the skin. Once the condition starts to improve it may be possible to reduce the dose to once or twice a day. Try to apply your cream at the same times each day. Use the cream for as long as directed by your doctor. If you forget to use Metosyn FAPG cream If you forget to apply the cream at the correct time, do so as soon as you remember.
If accidentally swallowed If you accidentally swallow the cream, contact your nearest doctor or hospital. If you have any further questions on the use of this medicine ask your doctor or pharmacist.
Like all medicines Metosyn FAPG cream can cause side effects, although not everybody gets them. The following side effects have been reported but how often they occur is unknown:
METOSYN FAPG CREAM Keep this medicine out of the sight and reach of children. It could harm them. Store Metosyn FAPG cream below 30°C. Keep the cream in the tube it came in. Do not use this medicine after the expiry date which is stated on the tube and carton. The expiry date refers to the last day of that month. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Metosyn FAPG cream contains The active substance is fluocinonide. Metosyn FAPG cream contains 0.05% w/w fluocinonide. The other ingredients are hexanetriol, stearyl alcohol, citric acid, polyethylene glycol, propylene glycol [E1520]. What Metosyn FAPG cream looks like and contents of the pack Metosyn FAPG cream comes in tubes of 25 and 100 grams.
Marketing authorisation holder: Reig Jofre UK Ltd, Follaton House, Plymouth Road, Totnes, Devon, TQ9 5NE, UK. Manufacturer: Bioglan AB, PO Box 50310, S-202 13 Malmö, Sweden. 'Metosyn' is a registered trademark. This leaflet was last revised in September 2025
Metosyn (Fluocinonide 0.05% w/w) Cream 25g comes as cream containing 25g. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Metosyn (Fluocinonide 0.05% w/w) Cream 25g is fluocinonide.
This leaflet reproduces the patient information leaflet approved for Metosyn (Fluocinonide 0.05% w/w) Cream 25g, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Metosyn is suitable for treating a wide variety of inflammatory, pruritic and allergic disorders of the skin. It is indicated for topical application in the following conditions:
Eczema and dermatitis; atopic eczema, seborrhoeic dermatitis, discoid eczema, contact dermatitis, neuro-dermatitis, prurigo, psoriasis (excluding widespread plaque psoriasis), lichen planus, discoid lupus erythematosus.
Metosyn FAPG cream may be used for wet or dry lesions.
Adults
A small quantity of Metosyn' FAPG cream should be applied three to four times daily to the affected area and massaged well in.
Once improvement is apparent, usage may be reduced to twice or even once daily.
Children
Under one year: Metosyn preparations are not advised in the treatment of children under one year of age.
Over one year: As adult dose, however, it is recommended that treatment should not normally be extended beyond five days and occlusion in such cases should not be used.
Elderly
As adult dose.
It is recommended that Metosyn is used undiluted.
Metosyn is contraindicated in rosacea, acne and peri-oral dermatitis. As with all topical steroids, Metosyn is contra-indicated in tuberculous, syphilitic, fungal and viral infections of the skin. The product should not be used for napkin eruption or anogenital pruritus.
Long-term continuous topical steroid therapy can produce atrophic skin changes and dilation of the superficial blood vessels particularly when occlusive dressings are used or where skin folds are involved. Prolonged use of topical steroids or treatment of extensive areas, even without occlusion, can result in sufficient absorption of the steroid to produce the features of hypercorticalism and underlying adrenal suppression, especially in infants and children.
Long term use of topical steroids can result in the development of rebound flares after stopping treatment (topical steroid withdrawal syndrome). A severe form of rebound flare can develop which takes the form of a dermatitis with intense redness, stinging and burning that can spread beyond the initial treatment area. It is more likely to occur when delicate skin sites such as the face and flexures are treated. Should there be a reoccurrence of the condition within days to weeks after successful treatment a withdrawal reaction should be suspected. Reapplication should be with caution and specialist advise is recommended in these cases or other treatment options should be considered.
It is recommended that treatment on the face should not normally be extended beyond 5 days, and occlusion in such cases should not be used.
Where there is bacterial infection associated with an inflammatory skin condition, Metosyn should only be administered if adequate antibacterial cover is also given.
When using topical steroids to treat psoriasis there are risks of rebound relapse following the development of tolerance, and of generalised pustular psoriasis. Impairment of the barrier function of the skin may lead to local and systemic toxicity. Careful patient supervision is important tolerance, and of generalised pustular psoriasis. Impairment of the barrier function of the skin may lead to local and systemic toxicity. Careful patient supervision is important.
Treatment should be discontinued if unfavourable reactions are seen.
Absorption is greatest where the skin is thin or raw.
The label will state strong steroid.
None known
Pregnancy: There is inadequate evidence of safety in human pregnancy. Topical administration of steroids to pregnant animals can cause abnormalities of foetal development, including cleft palate and intrauterine growth retardation. There may therefore be a very small risk of such effects on the human foetus.
Lactation: Topical steroids should not be applied to the breasts prior to nursing. When topical steroid treatment is considered necessary for other parts of the body, both the amount applied and the length of treatment should be minimised.
No precautions are necessary.
With Metosyn side effects are extremely rare but, as with all topical steroids, the occasional patient may show an adverse reaction such as hypersensitivity. Irritation at the site of application may occur infrequently. Extensive treatment, particularly involving occlusive dressings or where skin folds are involved, can result in both local atrophic changes, such as striae, skin thinning and telangiectasia, and systemic effects such as adrenal suppression.
The use of topical steroids on infected lesions, without the addition of appropriate anti-infective therapy, can result in the spread of opportunist infection.
The eyes should be avoided.
Local side effects include contact dermatitis, perioral dermatitis, acne, or worsening of acne or acne rosacea, mild depigmentation which may be reversible and hypertrichosis.
Withdrawal reactions - redness of the skin which may extend to areas beyond the initial affected area, burning or stinging sensation, itch, skin peeling, oozing pustules. (see section 4.4). The frequency of this adverse reaction is not known (cannot be estimated from the available data).
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Overdose (Symptoms, Emergency Procedures, Antidotes)
A 25g tube of Metosyn FAPG cream contains 12.5mg of fluocinonide. Toxic effects are not likely to occur following accidental ingestion. Similarly, the components of the vehicle, singly or collectively, have not been shown to produce toxic effects in these quantities.
Ask anything about Metosyn (Fluocinonide 0.05% w/w) Cream 25g. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.